IMUNON, Inc., formerly known as Celsion, was founded in Lawrenceville, New Jersey. The company is a clinical-stage biotechnology firm dedicated to developing innovative treatments that leverage the body's natural mechanisms to produce safe, effective, and lasting responses for a wide range of diseases. IMUNON focuses on creating proprietary immunology and DNA-based platforms and products, targeting some of the most challenging medical conditions. Their current projects include a Phase II clinical trial for ovarian cancer.
Notable figures associated with IMUNON include experienced scientists and industry leaders who have contributed to the company's research and development efforts. The company has attracted investment from reputable biotech investors, supporting its mission to advance groundbreaking medical treatments. IMUNON’s achievements include significant progress in clinical trials and the development of novel therapeutic platforms, positioning it as a promising player in the biotech industry with a potential for substantial impact on global health.
